Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,041 to 1,060 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| New insights on the interplays between m6A modifications and microRNA or lncRNA in gastrointestinal cancers. | Front Cell Dev Biol | 2023 | 37404673 | PubTator, text mining | PubMed |
| Modulation of miR-146b by N6-methyladenosine modification remodels tumor-associated macrophages and enhances anti-PD-1 therapy in colorectal cancer. | Cell Oncol (Dordr) | 2023 | 37402945 | PubTator, text mining | PubMed |
| The role of m6A demethylase FTO in chemotherapy resistance mediating acute myeloid leukemia relapse. | Cell Death Discov | 2023 | 37402730 | PubTator, text mining | PubMed |
| N6 -methyladenosine-modified FAM111A-DT promotes hepatocellular carcinoma growth via epigenetically activating FAM111A. | Cancer Sci | 2023 | 37400994 | PubTator, text mining | PubMed |
| Regulation of IFNβ expression: focusing on the role of its promoter and transcription regulators. | Front Microbiol | 2023 | 37396372 | PubTator, text mining | PubMed |
| Constructing a novel signature and predicting the immune landscape of colon cancer using N6-methylandenosine-related lncRNAs. | Front Genet | 2023 | 37396046 | PubTator, text mining | PubMed |
| m 6A methylation in cellular senescence of age-associated diseases. | Acta Biochim Biophys Sin (Shanghai) | 2023 | 37394885 | PubTator, text mining | PubMed |
| Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7. | Mol Cancer | 2023 | 37393311 | PubTator, text mining | PubMed |
| Epigenetic modification of m6A regulator proteins in cancer. | Mol Cancer | 2023 | 37391814 | PubTator, text mining | PubMed |
| Biomolecular Condensates in Myeloid Leukemia: What Do They Tell Us? | Hemasphere | 2023 | 37388925 | PubTator, text mining | PubMed |
| Radiotherapy-induced ferroptosis for cancer treatment. | Front Mol Biosci | 2023 | 37388241 | PubTator, text mining | PubMed |
| The mRNA methyltransferase Mettl3 modulates cytokine mRNA stability and limits functional responses in mast cells. | Nat Commun | 2023 | 37386028 | PubTator, text mining | PubMed |
| High glucose induces tau hyperphosphorylation in hippocampal neurons via inhibition of ALKBH5-mediated Dgkh m6A demethylation: a potential mechanism for diabetic cognitive dysfunction. | Cell Death Dis | 2023 | 37385994 | PubTator, text mining | PubMed |
| ALKBH5/YTHDF2-mediated m6A modification of circAFF2 enhances radiosensitivity of colorectal cancer by inhibiting Cullin neddylation. | Clin Transl Med | 2023 | 37381158 | PubTator, text mining | PubMed |
| m6A Regulates the Stability of Cellular Transcripts Required for Efficient KSHV Lytic Replication. | Viruses | 2023 | 37376680 | PubTator, text mining | PubMed |
| DNA Glycosylases Define the Outcome of Endogenous Base Modifications. | Int J Mol Sci | 2023 | 37373453 | PubTator, text mining | PubMed |
| Adenosine Methylation Level of miR-125a-5p Promotes Anti-PD-1 Therapy Escape through the Regulation of IGSF11/VSIG3 Expression. | Cancers (Basel) | 2023 | 37370798 | PubTator, text mining | PubMed |
| K235 acetylation couples with PSPC1 to regulate the m6A demethylation activity of ALKBH5 and tumorigenesis. | Nat Commun | 2023 | 37369679 | PubTator, text mining | PubMed |
| Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery. | Adv Drug Deliv Rev | 2023 | 37369262 | PubTator, text mining | PubMed |
| New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions. | Cancer Metastasis Rev | 2023 | 37368179 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=53